U.S. Skin Care Is Bright Spot As J&J Consumer Sales Dip
This article was originally published in The Rose Sheet
Executive Summary
Sales of Neutrogena brand skin-care products helped propel 2.7% growth in Johnson & Johnson’s U.S. skin-care division for fiscal 2012. However, global economic weakness led to an overall 2.6% drop for the firm’s skin-care business overall.
You may also be interested in...
FDA Flags J&J For Inadequate Oversight Of Consumer Devices
Though the firm claims to have come a long way in improving management of OTC pharma quality control since its 2009/2010 recalls, a May 22 warning letter regarding post-market monitoring and pre-market notifications for K-Y moisturizers suggests consumer devices are not getting the same level of attention.
ICCS President Hill On Growing Regulatory Confidence In Alternative Testing Methodologies
In the year since its establishment, the International Collaboration on Cosmetics Safety has worked to engage with regulators as they build frameworks for assessing cosmetic safety without animal tests. ICCS president and CEO Erin Hill discusses current challenges and what lies ahead.
Hawaii Contemplates Measures To Increase Access To Sunscreens Following Sunscreen Bans
Hawaii looks to “ease the burden” of finding reef-safe sunscreens by distributing it to sunseekers at beaches. The proposed legislation comes roughly three years after the Aloha State began prohibiting sale of oxybenzone- or octinoxate-containing sunscreen products due to concerns about potential harm to coral.